ZEALAND PHARMA A/S: Financial statements 2024
CVR: 20045078
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
ZEALAND PHARMA A/S (CVR 20045078) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 62,691,000 and a net result of DKK -1,078,828,000 compared with DKK -703,739,000 the year before. That is a decrease of 81.7% compared with the year before. The profit margin was -1,720.9%. Equity in the 2024 report amounted to DKK 8,616,742,000. The solvency ratio was 90.6%. The company had 235 employees in the financial year.
- Revenue
- DKK 62,691,000
- Gross Profit
- DKK 54,817,000
- Profit/Loss
- DKK -1,078,828,000
- Equity
- DKK 8,616,742,000
- Total Assets
- DKK 9,505,600,000
- Employees
- 235
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 62.7M | 54.8M | -1.1B | 8.6B | 235 |
| 2023 | 342.8M | 323.6M | -703.7M | 1.6B | 235 |
| 2022 | 104M EUR | 104M EUR | -1.2B EUR | 815.9M EUR | 247 |
| 2021 | 292.6M | 173.8M | -1B | 927.8M | 346 |
| 2020 | 353.3M | 262.7M | -846.7M | 1.2B | 297 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2024 to September 30, 2024.
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2024 to June 30, 2024.
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2024 to March 31, 2024.
ZEALAND PHARMA A/S has published its annual report for 2023. Revenue came to DKK 342,788,000, and the net result was DKK -703,739,000.
As of March 20, 2024, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ZEALAND PHARMA A/S.
As of March 20, 2024, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ZEALAND PHARMA A/S.
As of March 20, 2024, EY Godkendt Revisionspartnerselskab has stepped down as auditor of ZEALAND PHARMA A/S.
As of March 20, 2024, Ludovic Tranholm Otterbein has joined the board of directors of ZEALAND PHARMA A/S.
As of March 20, 2024, Nikolaj Frederik Beck has joined the board of directors of ZEALAND PHARMA A/S.
As of March 20, 2024, Adam Krisko Nygaard has joined the board of directors of ZEALAND PHARMA A/S.
About ZEALAND PHARMA A/S
ZEALAND PHARMA A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 1997. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ZEALAND PHARMACEUTICALS A/S and PEPTIDE PROBE TECHNOLOGIES ApS. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The board consists of Alf Gunnar Martin Nicklasson (chair), Kirsten Aarup Drejer, Adam Krisko Nygaard and Anneline Nansen. The company's owners include ZEALAND PHARMA A/S, Van Herk Investments B.V. and Van Herk Management Services B.V.. The company has 575 employees (2026). In 2025, the company reported revenue of DKK 9,214,860,000 and a net result of DKK 6,455,008,000 compared with DKK -1,078,828,000 the year before. Equity in the 2025 report amounted to DKK 14,830,613,000.
